“Fear and pain — together referred to as distress — are among the most common negative effects of vaccine injections,” says Dr. Anna Taddio, Leslie Dan Faculty of Pharmacy, University of… read more.
Capricor Therapeutics (NASDAQ: CAPR) will present new data on Deramiocel, its lead investigational therapy for Duchenne muscular dystrophy (DMD), at the 31st Annual Congress of the World Muscle… read more.
Actinogen Medical is pleased to announce that following the final trial participant visit yesterday in the USA, the Company can now confirm that topline results for the XanaMIA… read more.
Adults 65 and older with cognitive disorders such as dementia, are more likely to suffer negative effects from drugs that treat central nervous system conditions including anxiety, sleep… read more.
Johnson & Johnson announced positive topline results from the pivotal Phase 3 study evaluating CAPLYTA (lumateperone) for the treatment of manic episodes with or without mixed features in… read more.
SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today… read more.
AbbVie has presented new real-world data on VRAYLAR® (cariprazine) at Psych Congress 2026 in New Orleans, including results from two prospective observational studies in major depressive disorder (MDD)… read more.
A five-year, $3.4 million grant from the National Institutes of Health is powering work by an interdisciplinary team of researchers at The University of Texas at Dallas investigating… read more.
Eisai Co., Ltd. and Biogen Inc. announced that once weekly lecanemab-irmb subcutaneous injection (brand name: LEQEMBI IQLIK) is now available in the U.S. for initiation therapy for early… read more.
Facing major surgery is stressful, but for older adults, unaddressed anxiety and depression can impede physical recovery. A clinical trial led by researchers at Washington University School of… read more.
In the 1970s, psychiatric diagnoses were marked by considerable uncertainty and disagreement. Since then, organisations such as the American Psychiatric Association and the World Health Organization (WHO) have… read more.
Eisai Co., Ltd. and Biogen Inc. announced that the National Medical Products Administration (NMPA) of China has approved the subcutaneous formulation (subcutaneous autoinjector: SC-AI), the anti-amyloid beta (Aβ)… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
